Valuation: Travere Therapeutics, Inc.

Market Cap 4.94B 4.41B 4.08B 3.69B 6.91B 469B 7.03B 49.06B 19.42B 246B 18.55B 18.15B 775B P/E 2026 *
-284x
P/E 2027 * 19x
Enterprise Value 4.98B 4.45B 4.11B 3.73B 6.97B 473B 7.09B 49.47B 19.59B 248B 18.7B 18.3B 781B EV / Sales 2026 *
6.83x
EV / Sales 2027 * 4.36x
Free-Float
95.33%
Yield 2026 *
-
Yield 2027 * -
1 day-4.03%
1 week+1.53%
Current month-14.47%
1 month-15.83%
3 months-11.15%
6 months+23.37%
Current year+31.80%
1 week 49.74
Extreme 49.74
54.83
1 month 49.46
Extreme 49.46
61.87
Current year 22.59
Extreme 22.59
68.73
1 year 22.59
Extreme 22.59
68.73
3 years 5.12
Extreme 5.12
68.73
5 years 5.12
Extreme 5.12
68.73
10 years 5.12
Extreme 5.12
68.73
Manager TitleAgeSince
Chief Executive Officer 53 2019-01-03
Director of Finance/CFO 42 2022-08-30
Chief Tech/Sci/R&D Officer 51 2022-01-03
Director TitleAgeSince
Chairman 75 2016-05-17
Chairman 59 2015-06-07
Director/Board Member 59 2015-03-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/17/26 Exercice

Executive/Senior Manager

24,846 0.0267%
9/17/26 Exercice

Chief Executive Officer

325,479 0.3500%
9/16/26 Exercice

Chief Technology Officer

338,550 0.3641%
Change 5-day change 1-year change 3-year change Capi.($)
-4.03%+1.53%+78.90%+616.36% 4.94B
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+7.50%+11.01%+73.48% 54.89B
+0.57%+4.60%+10.07%+92.86% 53.28B
-0.02%+4.17%+26.43%+51.34% 45.81B
-1.39%+2.14%+21.58%+123.40% 43.46B
+0.69%+5.96%+252.84%+927.30% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+5.68%+36.43%+27.54% 23.76B
Average -0.12%+0.23%+52.30%+203.94% 38.68B
Weighted average by Cap. +0.35%+0.54%+48.11%+165.66%

Financials

2026 *2027 *
Net sales 729M 651M 602M 545M 1.02B 69.25B 1.04B 7.24B 2.87B 36.28B 2.74B 2.68B 114B 1.09B 970M 896M 812M 1.52B 103B 1.54B 10.78B 4.27B 54.01B 4.08B 3.99B 170B
Net income -9.53M -8.51M -7.86M -7.12M -13.33M -905M -13.55M -94.61M -37.46M -474M -35.77M -35M -1.49B 234M 209M 193M 175M 327M 22.17B 332M 2.32B 918M 11.62B 877M 858M 36.62B
Net Debt 41.4M 36.97M 34.15M 30.95M 57.9M 3.93B 58.86M 411M 163M 2.06B 155M 152M 6.49B -208M -186M -172M -156M -292M -19.79B -296M -2.07B -819M -10.37B -782M -766M -32.69B
Projected Income Statement - Annual - Travere Therapeutics, Inc.
Logo Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Employees
497
Date Price Change Volume
26-10-23 US$50.36 -3.95% 487,033
26-10-22 US$52.43 -0.29% 1,774,177
26-10-21 US$52.58 +0.54% 2,164,173
26-10-20 US$52.30 +3.58% 2,057,650
26-10-19 US$50.49 +1.79% 1,315,520
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Travere Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
52.43USD
Average target price
75.21USD
Spread / Average Target
+43.46%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Travere Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. TVTX Stock